- Conditions
- Human Immuno-deficiency Virus (HIV) Disease
- Interventions
- Budigalimab, Placebo for Budigalimab, ABBV-382, Placebo for ABBV-382
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 33 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 241–264
of 2,291
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HIV Infections
- Interventions
- Potent HAART during acute or early HIV-1 infection
- Drug
- Lead sponsor
- Rockefeller University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- HIV Infections
- Interventions
- Not listed
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Chronic Obstructive Pulmonary Disease, HIV, Emphysema
- Interventions
- blood draw, questionnaires, Lung function testing, Six-Minute walk test, Quantitative CT scans, Nasal secretion and cell collection, Echocardiogram
- Procedure · Radiation
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 232 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Influenza
- Interventions
- Oseltamivir Phosphate, ADS-8902
- Drug
- Lead sponsor
- Adamas Pharmaceuticals, Inc.
- Industry
- Eligibility
- 1 Year to 65 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 16
- States / cities
- San Francisco, California • Hollywood, Florida • Miramar, Florida + 11 more
- Conditions
- HIV Infections
- Interventions
- VRC rAd5 vaccine (rAd5 gag-pol/env A/B/C), rAd5 env A, rAd5 env B, rAd5 env C, rAd5 gag-pol, Placebo Vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2017
- U.S. locations
- 8
- States / cities
- San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 4 more
- Conditions
- HIV Infections
- Interventions
- Early Treatment with HAART, No treatment, HAART Treatment - standard care
- Drug · Other
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 24 Years
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 20
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 12 more
- Conditions
- HIV
- Interventions
- Etravirine pharmacokinetics in breast milk and plasma
- Drug
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 9 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- HIV Infections
- Interventions
- Saquinavir, Lamivudine, Stavudine, Zidovudine, Zalcitabine, Didanosine
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more
- Conditions
- HIV Infections
- Interventions
- LC002 standard vaccination, LC002 high-dose vaccination, LC002 placebo vaccination
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 5
- States / cities
- Sacramento, California • Chicago, Illinois • Cleveland, Ohio + 1 more
- Conditions
- Hepatitis C, HIV Infections
- Interventions
- telaprevir or matching placebo, peginterferon alfa-2a, ribavirin (fixed dose), ribavirin (weight-based dose)
- Drug · Biological
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 11
- States / cities
- Beverly Hills, California • San Diego, California • San Francisco, California + 8 more
- Conditions
- HIV-1 Infection
- Interventions
- 3BNC117, Antiretroviral Treatment Interruption
- Drug · Other
- Lead sponsor
- Rockefeller University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Opioid-use Disorder, HIV-1-infection, Immune Activation, Inflammation, Methadone, Buprenorphine, Naltrexone, Antiretroviral Treatment
- Interventions
- Methadone, Buprenorphine/naloxone, XR-Naltrexone
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- HIV Infections
- Interventions
- 3BNC117-LS, 10-1074-LS
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Pneumonia, Pneumocystis Carinii, HIV Infections
- Interventions
- Trimethoprim, Sulfamethoxazole, Leucovorin calcium
- Drug
- Lead sponsor
- Lederle Laboratories
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- HIV Infection
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2011
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland
- Conditions
- HIV Seropositivity, Adherence, Medication
- Interventions
- MI sessions, TMQQ, Type of compensation
- Behavioral
- Lead sponsor
- New York University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- AIDS-Related Hodgkin Lymphoma, AIDS-Related Non-Hodgkin Lymphoma, HIV Infection, Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma
- Interventions
- Gene-Modified HIV-Protected Hematopoietic Stem Cells, Laboratory Biomarker Analysis, Transplant Conditioning
- Biological · Other
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years to 66 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Opiate Addiction
- Interventions
- Onsite treatment, Enhanced referral, Buprenorphine
- Behavioral · Drug
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 3
- States / cities
- New York, New York • The Bronx, New York
- Conditions
- Harm Reduction, HIV Infections, Drug Use
- Interventions
- Biktarvy 50Mg-200Mg-25Mg Tablet, HIV care
- Drug · Other
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- HIV Infections
- Interventions
- Amprenavir/ritonavir, Saquinavir/ritonavir
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 18 more
- Conditions
- HIV Infections
- Interventions
- Enfuvirtide
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 525 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 27 more
- Conditions
- Human Immunodeficiency Virus (HIV)
- Interventions
- Etravirine, Ritonavir, Darunavir
- Drug
- Lead sponsor
- Tibotec, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 22
- States / cities
- Long Beach, California • Los Angeles, California • San Francisco, California + 19 more
- Conditions
- HIV Infections
- Interventions
- Abacavir sulfate, Amprenavir, Efavirenz, Adefovir dipivoxil
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 5
- States / cities
- Beverly Hills, California • Denver, Colorado • Atlanta, Georgia + 2 more